SecBot SecBot
PRESS-RELEASE ·Filed Mar 26, 2026

APGE

Apogee Therapeutics
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor pipeline advancement, particularly phase progression of zumilokibart; assess whether capital raise supports extended runway without near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.82
T+0 close · Mar 26, 2026 · via day close
Latest settled
+70.66%
T+60 · $132.81
Vs SPY
+54.59%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 27 $77.82entry
  2. T+1 · 8mo ago +1.16%α +1.51% · $78.72
  3. T+5 · 8mo ago +7.95%α +4.09% · $84.01
  4. T+20 · 7mo ago +11.12%α −1.63% · $86.47
  5. T+60 · 5mo ago +70.66%α +54.59% · $132.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics completed a public offering of 5,750,000 shares at $70.00 per share, raising approximately $403 million in gross proceeds. The capital will support development of its clinical-stage biologics pipeline in inflammatory and immunology indications.

Key Financial Metrics

Deal Value
$403.0M

Key Facts

  • Apogee Therapeutics closed an underwritten public offering of 5,750,000 shares of common stock
  • Offering price was $70.00 per share, with full exercise of underwriters' option for 750,000 additional shares
  • Aggregate gross proceeds were approximately $403 million before expenses
  • Proceeds will be used to advance clinical development of Apogee's biologics pipeline, including zumilokibart (APG777) for atopic dermatitis, asthma, and EoE
  • Jefferies, TD Cowen, Stifel, and Guggenheim Securities acted as joint book-running managers

Financial Impact

$403 million in gross proceeds, dilutive to existing shareholders by approximately 5.75M shares

dilutioncashequity

Risk Factors

  • Dilution to existing shareholders from issuance of new shares
  • Execution risk in advancing clinical programs despite funding

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3263384

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 19m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026